ライフサイエンスコーパス: liver biopsy

1 eventually on histological examination from liver biopsy.

2 on in participants undergoing a transjugular liver biopsy.

3 s predicted to reduce harms from unnecessary liver biopsy.

4 false-positive testing and the frequency of liver biopsy.

5 turnover; oral glucose tolerance test; and a liver biopsy.

6 outcome was the degree of bile duct loss on liver biopsy.

7 erwent bariatric surgery and intra-operative liver biopsy.

8 n the cohort except 1 were managed without a liver biopsy.

9 or 3-5 weeks prior to a clinically indicated liver biopsy.

10 rwent clinical and laboratory evaluation and liver biopsy.

11 ho met criteria, 56 had TE, whereas 34 had a liver biopsy.

12 The results were compared with those from liver biopsy.

13 nd had a higher interobserver agreement than liver biopsy.

14 in a cohort of NAFLD patients who underwent liver biopsy.

15 M probe), and ARFI within two weeks prior to liver biopsy.

16 The diagnosis of NASH currently requires a liver biopsy.

17 eferred for HVPG measurement or transjugular liver biopsy.

18 nderwent a detailed metabolic assessment and liver biopsy.

19 respectively, for all subjects who underwent liver biopsy.

20 diatric CF liver disease (CFLD) validated by liver biopsy.

21 f having NAFLD who underwent contemporaneous liver biopsy.

22 iver procurement underwent a FibroScan and a liver biopsy.

23 rty-one of the children with NAFLD underwent liver biopsy.

24 s a means for predicting disease severity on liver biopsy.

25 ts with abnormal results were considered for liver biopsy.

26 icipants who were scheduled for transjugular liver biopsy.

27 se detected by surveillance and confirmed by liver biopsy.

28 iagnosed by imaging, serum-based indices, or liver biopsy.

29 undergoing bariatric surgery and concomitant liver biopsy.

30 ast history of complication, and assessed on liver biopsy.

31 d with progression from steatosis to NASH in liver biopsies.

32 ification of the triradylglycerol content in liver biopsies.

33 eatment responses were correlated in patient liver biopsies.

34 sion localized to CK7(+) DR and LPCs in CFLD liver biopsies.

35 Histology was performed on liver biopsies.

36 esence of diffuse vascular C4d expression on liver biopsies.

37 T3 (n=15) or TG (n=17) using yearly protocol liver biopsies.

38 , Huh7 cells, primary hepatocytes, and human liver biopsies.

39 ormal amount of copper was noted in the core liver biopsies.

40 is >5 years after LT), assessed by follow-up liver biopsies.

41 At liver biopsy 1, mean %HCV-infected cells = 25.2% (95% co

42 Thirty patients had F0/F1 fibrosis stage at liver biopsy (10 with NASH), and 27 patients had signifi

43 is, or liver disease, except for the rate of liver biopsy (10.9% versus 1.8% [p = 0.013] in males; 9.

44 spective study, all patients who underwent a liver biopsy 1984-2009 at the National University Hospit

45 ts with NAFLD without diabetes and who had a liver biopsy (29 NAFLD-NO and 15 NAFLD-Ob) and 20 CTs wi

46 : 1) port placement, 2) liver retraction, 3) liver biopsy, 4) gastrocolic ligament dissection, 5) sta

47 In patients with liver biopsy, 88.2% had recurrent NAFLD, whereas 41.2% h

48 According to the degree of liver fibrosis at liver biopsy, 88.5%-96.8% of patients were correctly cla

49 were rejected for HBcAb+ (33%), HCV+ (18%), liver biopsy (9%), HBsAg+ (6%), neoplastic (6%), or infe

50 NAFLD was defined based on liver biopsy, abdominal imaging or ICD-coding and the ab

51 nance imaging and 39 required an unnecessary liver biopsy according to the recall policy.

52 ave elastography (Supersonic Aixplorer), and liver biopsy after an overnight fast.

53 nts who underwent SWE before their scheduled liver biopsy (age range, 18-76 years; mean age, 49 years

54 ts (56.7% female) who underwent MRE, TE, and liver biopsy analysis (using the histologic scoring syst

55 ta from 450 consecutive adults who underwent liver biopsy analysis for suspected NAFLD at 7 centers i

56 l study, 67 children with CFLD had dual-pass liver biopsies and 104 age- and sex-matched CF children

57 e of HCV RNA and ISG mRNA detection in human liver biopsies and applied it to study the interaction o

58 Liver biopsies and clinical data were obtained from infa

59 rosis (col1a1 IHC) was performed on terminal liver biopsies and compared with stereologically sampled

60 Liver biopsies and HVPG measurements (only for patients

61 nificantly up-regulated both in HCV-positive liver biopsies and in HCV-infected primary human hepatoc

62 characterized the expression of hCH25H using liver biopsies and primary human hepatocytes.

63 is (stage 2 or lower) was observed in 18% of liver biopsies and stage 3 was observed in 0.7%, but cir

64 Of the 139 enrolled participants, 108 with a liver biopsy and having at least one noninvasive biomark

65 After standard-of-care transjugular liver biopsy and HVPG pressure measurements, participant

66 opsy at baseline followed by a repeat paired liver biopsy and MRE assessment.

67 r 72 weeks of obeticholic acid or placebo by liver biopsy and MRI (scanners from different manufactur

68 y recognition of HLH and B. henselae through liver biopsy and serological tests led to the patient's

69 events occurred (pain after a post-treatment liver biopsy and vertigo), both unrelated to study drugs

70 /14-11/07/18, 114 HIV-HBV adults underwent a liver biopsy and were followed for a median of 3 years (

71 nce with infected primary human hepatocytes, liver biopsies, and hepatoma cell lines.

72 ating global transcriptomic data, from human liver biopsies, and metabolic flux data, measured across

73 um volume centers, infections, hemodialysis, liver biopsy, and length of stay > 10 days were the pred

74 chniques with contrast administration and/or liver biopsy are mostly necessary for establishing diagn

75 Using liver biopsy as a starting point, we analyzed the develo

76 dictive models of liver retrievability using liver biopsy as the gold standard have led to the follow

77 collagen content and lobular inflammation on liver biopsy, as well as improvements in serum biomarker

78 emonstrated that drug-induced improvement in liver biopsy-assessed histopathology is representative f

79 NAFLD who underwent contemporaneous MRE and liver biopsy at baseline followed by a repeat paired liv

80 Seven hundred fifteen (52.7%) patients had a liver biopsy at diagnosis.

81 liver cancer and genetic studies of a human liver biopsy atlas with the aim of identifying putative

82 alcoholic fatty liver disease still requires liver biopsy, biomarkers to detect advanced fibrosis are

83 A similar high expression was seen in liver biopsies, but expression was considerably lower in

84 onclude that minimally invasive percutaneous liver biopsies can be used with relatively high efficien

85 In the liver biopsy cohort, 188 subjects (13%) were carriers of

86 Most performed selective liver biopsy, commonly for steatosis, raised transaminas

87 expression is significantly elevated in HCV+ liver biopsies compared to hepatitis B virus (HBV+) and

88 in subjects with severe steatosis (>/=66% at liver biopsy) compared to those without (F0-F1 6.9 versu

89 r suspected infection or relapse followed by liver biopsy comprised the study group.

90 e data, CEACAM1 expression in 60 human donor liver biopsies correlated negatively with activation of

91 In the Liver Biopsy Cross-Sectional Cohort, a total of 1149 ind

92 ents) and 1149 European individuals from the Liver Biopsy Cross-Sectional Cohort.

93 Fungal blood or liver biopsy cultures are generally negative, suggesting

94 cted clinical, serologic, (1)H-MRS PDFF, and liver biopsy data from 94 adult patients with increased

95 A liver biopsy demonstrated centrilobular cholestasis and

96 In liver biopsies, disorders of the cholangiocytes primary

97 health systems in the United States who had liver biopsies during 2001-2012.

98 demonstrated in all 5 patients who received liver biopsies during the study.

99 portion of individuals with NAFLD worldwide, liver biopsy evaluation is impractical, and noninvasive

100 No RCTs examined sequential liver biopsy findings.

101 uses of chronic liver disease, who underwent liver biopsy for abnormal liver biochemistry and/or clin

102 udy included 46 adult patients who underwent liver biopsy for chronic viral hepatitis (n=19) or other

103 Six patients on therapy underwent a liver biopsy for flow cytometric analysis.

104 marker represents a promising alternative to liver biopsy for NASH diagnosis and monitoring.

105 mples were obtained from patients undergoing liver biopsy for suspected NAFLD or NASH, or during live

106 as evaluated in 1,201 patients who underwent liver biopsy for suspected NASH; 427 were evaluated for

107 sulin-treated type 2 diabetes (T2IN) who had liver biopsy formed two comparative cohorts.

108 e cAMR score distribution on 1-year protocol liver biopsy found that 41% had a score less than 13; 27

109 We compared paired liver biopsies from 122 of 139 children with NAFLD (74%

110 We obtained liver biopsies from 2 patients with WD in Italy and live

111 and Switzerland (validation cohort 1) and in liver biopsies from 20 patients (9 received corticostero

112 esponse [SVR]; n=1 relapse) and unpaired EOT liver biopsies from 25 patients (n=17 SVR; n=8 relapse).

113 Steatosis was evaluated in liver biopsies from 268 adult recipients.

114 Paired liver biopsies from 43 patients who received subcutaneou

115 Findings were validated using liver biopsies from 48 consecutive patients with severe

116 to quantify residual intrahepatic cccDNA in liver biopsies from 56 chronically HBV infected patients

117 Liver biopsies from 63 C282Y homozygous patients were as

118 using paired pre- and end-of-treatment (EOT) liver biopsies from 8 patients (n=7 sustained virologic

119 Using liver biopsies from adults with early-stage AATD and the

120 We studied: (1) 180 liver biopsies from ARLD patients; (2) 20 ARLD explant l

121 Liver biopsies from GAN DIO-NASH mice and NASH patients

122 ific target genes was also observed in human liver biopsies from HCC patients compared to healthy pat

123 e time of Kasai portoenterostomy, along with liver biopsies from infants without BA (controls).

124 Moreover, E2F1 expression was increased in liver biopsies from obese, glucose-intolerant humans com

125 Increased phospho-MLKL staining in liver biopsies from patients with autoimmune hepatitis s

126 Analysis of 70 liver biopsies from patients with chronic HBV infection

127 We obtained transjugular liver biopsies from patients with hepatitis C virus-asso

128 Reduced Mfn2 expression was detected in liver biopsies from patients with non-alcoholic steatohe

129 Fifty-nine liver biopsies from patients, that were serologically pr

130 Liver biopsies from PSC patients were collected from sev

131 We identified patients who have had liver biopsy from a computerized database (DIAMOND; Hico

132 IHC staining of a liver biopsy from a patient with FLUX-induced liver inju

133 d liraglutide and underwent end-of-treatment liver biopsy had resolution of definite non-alcoholic st

134 Until now, liver biopsy has been the gold standard for identifying

135 Classically, serum ferritin and liver biopsy have been used to monitor patient response

136 ced disease is challenging and may require a liver biopsy, highlighting the urgent need for reliable,

137 y of the model by head-to-head comparison of liver biopsy histological and transcriptome changes in G

138 Liver biopsy histology and transcriptome signatures were

139 y fistula which developed incidentally after liver biopsy in a 10-year-old boy with chronic hepatitis

140 resonance (MR) spectroscopy with results of liver biopsy in a cohort of adult patients suspected of

141 and regional level and the potential role of liver biopsy in donor evaluation.

142 cluding telangiectasia, were demonstrated by liver biopsy in five of these patients.

143 plications of ultrasound-guided percutaneous liver biopsy in the diagnosis of space-occupying lesions

144 s as a test replacement strategy (to replace liver biopsy) in making key decisions in the management

145 In unpaired EOT liver biopsies, intrahepatic expression of fatty acid me

146 Ultrasound-guided percutaneous liver biopsy is an efficacious and safe technique for th

147 Ultrasound-guided percutaneous liver biopsy is considered the technique of choice for t

148 identify liver disease in such patients, but liver biopsy is necessary to definitively identify those

149 Currently liver biopsy is the gold standard for fibrosis assessmen

150 Liver biopsy is the gold standard method to assess nonal

151 ystems exist to characterize NAFLD and NASH, liver biopsy is the only accepted method for diagnosis o

152 Background Liver biopsy is the reference standard to diagnose nonal

153 Liver biopsy is the reference test for the assessment of

154 We compared the prognostic value of liver biopsy (LB) and FIB-4 index in patients with human

155 f using noninvasive tests (NITs) compared to liver biopsy (LB) in diagnosing cirrhosis.

156 ometry of intrahepatic T cells isolated from liver biopsy led to the targeted treatment with anti-tum

157 All patients received a liver biopsy, lifestyle assessment, blood tests, and QOL

158 sed by paired pretreatment and posttreatment liver biopsies, magnetic resonance elastography, magneti

159 Liver biopsy may increase the utilization rate of hBMI d

160 tially expressed serum miRNA with concordant liver biopsy mRNA demonstrates interaction between molec

161 ase over a 10-year period that had undergone liver biopsies (n = 363) were scored for the presence of

162 imization before and at clinically indicated liver biopsy (n = 119).

163 Patients undergoing liver biopsy (n = 69) provided fasting blood, fresh tiss

164 tion associated with invasive tests, such as liver biopsy, noninvasive imaging modalities for liver f

165 ither group are willing to under go a repeat liver biopsy (NS).

166 A set of 20 human liver biopsies obtained from organs intended for transpl

167 was performed on both pre- and posttreatment liver biopsies of 59 PIVENS patients randomized to VitE

168 AAT inclusions were detected in liver biopsies of 63% of subjects with the Pi*MZ genotyp

169 ymes of glutamine metabolism in vitro and in liver biopsies of chronic HCV patients.

170 The histopathologic findings of core liver biopsies of liver metastases identified by needle

171 REBP-interacting protein that is enriched in liver biopsies of nonalcoholic steatohepatitis (NASH) pa

172 -lambda receptor chain (IFN-lambdaR1) in 122 liver biopsies of patients with CHC and 53 control sampl

173 ion was decreased and c-Jun was increased in liver biopsies of patients with steatosis and NASH compa

174 s from a 24-week, phase 2 study, with serial liver biopsies, of patients with nonalcoholic steatohepa

175 are more prevalent in biliary fluid than in liver biopsy or blood serum after LT.

176 their baseline fibrosis classified by either liver biopsy or liver stiffness measurement (LSM).

177 nfection diagnosis with cirrhosis-defined by liver biopsy or mean FIB-4 score >5.88-and time to onset

178 l cancer and were scheduled for percutaneous liver biopsy or thermal ablation were eligible for this

179 iver fibrosis was assessed histologically by liver biopsy or transient elastometry.

180 Overall, 435 liver biopsy pairs from 282 patients without cirrhosis w

181 The cellular infiltrate in protocol liver biopsies (PB) following pediatric liver transplant

182 Prerecovery liver biopsy (PLB) allows histological evaluation of the

183 Percutaneous liver biopsy (PLB) is the "gold standard" in the diagnos

184 Key recommendations include: (1) liver biopsy, portal venous wedge pressure, and reversal

185 tohepatitis was replicated in 44 independent liver biopsies (r = 0.47, P = 0.0013).

186 tuberculosis immune reconstitution syndrome; liver biopsy remains a useful diagnostic procedure in th

187 Whereas liver biopsy remains the gold standard for staging of di

188 Analysis of paired liver biopsies revealed altered expression of genes asso

189 Histopathological examinations of liver biopsies revealed mild, periportally accentuated i

190 Liver biopsies revealed nonspecific liver damage includi

191 Evaluation of liver biopsies revealed that pegIFN-alpha induces hundre

192 A liver biopsy revealed interface hepatitis with IgG4 posi

193 patic venous portal gradient measurement and liver biopsy revealed no evidence of hepatic disease or

194 We obtained liver biopsy samples from 69 patients with chronic HCV i

195 We obtained fixed liver biopsy samples from 71 consecutive patients diagno

196 HCV replicon-harboring cells, as well as in liver biopsy samples from chronically HCV-infected patie

197 Ex vivo molecular MR imaging of liver biopsy samples from NASH and control patients conf

198 profiles were compared between seven paired liver biopsy samples taken before and 6 months after suc

199 Eleven human liver biopsy samples underwent MPO-Gd-enhanced MR imagin

200 Liver biopsy samples were analyzed by histology and scor

201 Liver biopsy samples were available for 1201 patients (9

202 Blood and liver biopsy samples were collected before treatment and

203 Liver biopsy samples, NIT results, and PROs (Short Form-

204 n/ID1 mRNA expression in chronic HCV patient liver biopsy samples.

205 teatohepatitis (NASH) mouse models and human liver biopsy samples.

206 MPO activity in NAFLD mouse models and human liver biopsy samples.

207 iRNA expression level was also measured from liver biopsy samples.

208 who underwent MRE, ARFI, and contemporaneous liver biopsies scored using the Nonalcoholic Steatohepat

209 Liver biopsy should be considered in patients with NAFLD

210 The liver biopsy showed a higher prevalence of fibrosis (P =

211 one patient had high transaminase levels and liver biopsy showed cystine crystals in the liver.

212 in HeLa cells, and electron microscopy of a liver biopsy showed dilated organelles suggestive of the

213 Features of liver biopsies significantly associated with death or li

214 Histologic analysis of liver biopsy specimens allows for grading and staging of

215 While methods for cccDNA quantification from liver biopsy specimens and cell lines expressing the vir

216 ved in vivo and demonstrate that fine-needle liver biopsy specimens can provide sufficient material t

217 th miRNA expression levels were lower in HCC liver biopsy specimens compared with normal liver RNA.

218 Importantly, enabling the use of fine-needle liver biopsy specimens for such high-resolution analyses

219 prospective study, we analyzed percutaneous liver biopsy specimens from 73 consecutive patients with

220 Thus, we analyzed serial liver biopsy specimens from adult liver recipients enrol

221 andem mass spectrometry and analyzed BMP6 in liver biopsy specimens from patients by immunohistochemi

222 In liver biopsy specimens from patients with acute hepatiti

223 All liver biopsy specimens from patients with late relapse w

224 Total RNA sequencing of liver biopsy specimens from the obese steatotic individu

225 ng CD4(+) T cells in peripheral blood and in liver biopsy specimens in comparison with those of CD4(+

226 mRNA displayed a significant increase in the liver biopsy specimens of chronically HCV-infected patie

227 hat miRNA-122 (miR-122) is down-regulated in liver biopsy specimens of patients with ALF and in aceta

228 ver tissue from a rat model of NAFLD, and in liver biopsy specimens of patients with simple steatosis

229 we mapped their topological distributions in liver biopsy specimens of two anti-hepatitis B e antigen

230 Analysis of human liver biopsy specimens revealed a correlation of DPP4 ex

231 A lymphocytic infiltrate was seen on liver biopsy specimens taken from 2 subjects with transa

232 )H-MRS), instead of collecting and analyzing liver biopsy specimens to detect steatosis.

233 approach for analysis of fine-needle patient liver biopsy specimens to investigate the role of histon

234 Liver biopsy specimens were analyzed by in situ hybridiz

235 Liver biopsy specimens, usually collected via the transj

236 nfected hepatocytes and chronic HCV-infected liver biopsy specimens.

237 3 expression in hepatocytes and HCV-infected liver biopsy specimens.

238 stinguishing benign from malignant tissue in liver biopsy specimens.

239 The degree of steatosis was evaluated from liver biopsy specimens.

240 ons for use with patient-derived fine-needle liver biopsy specimens.

241 ted by cytokeratin-7 immunohistochemistry in liver biopsies, staged for fibrosis, from 60 children wi

242 Liver biopsy still is regarded as the reference for diff

243 Transcriptomic analysis of liver biopsies taken prior to treatment suggested that T

244 representative NASH cohorts with associated liver biopsies, the gold standard for NASH diagnosis, pr

245 V-monoinfected patients who had a qualifying liver biopsy, the mean age at the time of biopsy was 50.

246 hepatitis (AH) often requires a transjugular liver biopsy (TJLB), a procedure that is not always read

247 Here we used HCV-infected cells and liver biopsies to study how HCV modulates the glutaminol

248 assess hepatic fat content and 11 underwent liver biopsy to assess the degree of disease severity.

249 changes for 52 weeks and underwent a second liver biopsy to confirm NASH resolution.

250 ohort, a total of 1149 individuals underwent liver biopsy to diagnose liver disease and disease sever

251 harts of deceased patients were reviewed for liver biopsy to evaluate for disease recurrence.

252 Time at risk was determined from the date of liver biopsy to the date of outcome or last follow-up ex

253 The latter were compared with liver biopsy transcriptomes from IA (n = 16) and IT (n =

254 Liver fibrosis was assessed by means of liver biopsy, transient elastography, and clinical cirrh

255 irrhosis was determined at screening using a liver biopsy, transient elastography, or serum biomarker

256 infection without cirrhosis (as assessed by liver biopsy, transient elastography, or serum markers).

257 Cirrhosis was identified by liver biopsy, ultrasound, endoscopic analysis, and bioch

258 This is the first liver biopsy-validated study of APRI and FIB-4 in pediat

259 and liver-related mortality of patients with liver biopsy verified fatty liver disease in a populatio

260 We also assessed whether liver biopsy versus follow-up with the same versus alter

261 sistent with the (1)H-MRS data, steatosis on liver biopsy was also significantly increased in patient

262 re obtained at weeks 12 and 36, and a second liver biopsy was obtained at week 36.

263 Liver biopsy was performed only if the confirmatory scan

264 Liver biopsy was used as the gold standard for diagnosin

265 of 330 patients who underwent pretherapeutic liver biopsy, we analyzed the HCC incidence in relations

266 Pretransplant liver biopsies were analyzed by immunostaining and elect

267 Liver biopsies were analyzed following challenge with 45

268 Liver biopsies were analyzed to define histologic and bi

269 Paired liver biopsies were available from 261 patients.

270 Intraoperative liver biopsies were categorized with NAFLD Activity Scor

271 Intraoperative liver biopsies were classified using NAFLD activity scor

272 Intraoperative core liver biopsies were collected from 165 subjects; 17 were

273 Liver biopsies were collected from 37 of the patients pr

274 Liver biopsies were collected when the study began and a

275 Liver biopsies were examined for the presence of fibrin,

276 V-infected patients who underwent at least 2 liver biopsies were included in this study.

277 Liver biopsies were performed 2 and 4 years off IS, and,

278 Liver biopsies were performed if clinically indicated.

279 erse events, laboratory results, imaging and liver biopsies were retrospectively collected.

280 Liver biopsies were then collected and patients were ass

281 clinical and demographic data who underwent liver biopsy were analyzed and clinicopathologically ass

282 rom 1 month to 17.2 years old) who underwent liver biopsy were analyzed.

283 Ballooning and/or inflammation at liver biopsy were associated with increased plasma BCAAs

284 Results Steatosis grades at liver biopsy were distributed as follows: S0, five patie

285 iver transplantation, and had a protocolized liver biopsy were evaluated (n = 230).

286 ected on the basis of a clinically indicated liver biopsy were excluded to better reflect general pop

287 orty patients with a clinical indication for liver biopsy were prospectively recruited for liver ECV

288 nts with chronic liver disease scheduled for liver biopsy were prospectively recruited from November

289 Consecutive NAFLD patients who underwent liver biopsy were prospectively recruited.

290 tive pediatric patients scheduled to undergo liver biopsy were studied with an ultrasonography-based

291 c resonance elastography (MRE) or historical liver biopsy, were randomized to receive cilofexor 100 m

292 ssociated liver injury had bile duct loss on liver biopsy, which was moderate to severe (<50% of port

293 atients; (2) 20 ARLD explant livers; (3) 213 liver biopsies with non-ARLD injury.

294 minotransferases and hepatic architecture in liver biopsies with simple steatosis.

295 agnosis of alcoholic fibrosis and cirrhosis; liver biopsy with Ishak score and collagen-proportionate

296 rospective analyses of patients with post-LT liver biopsies, with the exception of 2 studies that use

297 In 289 patients who underwent liver biopsy within 1 year of the MR elastography date,

298 Forty patients who had had a liver biopsy within the previous month were recruited.

299 Additional studies that use liver biopsies would allow for the assessment of pegbelf

300 Using both cutoffs, a liver biopsy would have been avoided in 229 (88%) of 261